Vivalytic | Candida auris
Vivalytic | Candida auris
Vivalytic | Candida auris
–
Detection of Candida auris
*Research Use Only
Qualitative RT-PCR detection of Candida auris
- Quick turnaround time of 30 minutes, beneficial for both the patient and for the containment of Candia auris and reducing transmission.
- Convenient 4 step process from sample entry to results. Suitable for use in laboratory and non-laboratory settings.
- Real-time PCR enables rapid and targeted detection up to 4 weeks after the onset of symptoms of the multidrug-resistant fungal Candia auris.
Clinical Significance
Candida auris is an emerging and often multidrug-resistant fungal species that poses a significant threat to public health. This yeast-like fungus can cause severe infections, primarily affecting individuals with compromised immune systems, those in healthcare facilities, or those with underlying medical conditions. Candida auris is particularly concerning due to its ability to persist on surfaces, leading to healthcare-associated outbreaks. Diagnosis can be challenging as it is often misidentified with other Candida species. Effective management involves prompt identification, strict infection control measures followed by treatment. The Vivalytic Candida auris test is an automated, qualitative in vitro diagnostic employing real-time PCR to detect Candida auris DNA from swabs taken from the human axilla, groin, nasal, and rectal areas.
This test serves to screen individuals at risk for colonisation, playing a crucial role in the prevention and control of Candida auris outbreaks and infections within healthcare settings.
Features
Sample Type: Swab
Sample Volume: 300 μl
Detection Method: Real-Time PCR
Time to result: 52 minutes
| Detectable Pathogens |
|---|
| Candida auris |
“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”
Vivalytic Workflow
Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.
To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.
The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.
Want to know more?
Contact us or visit our COVID-19 Monitoring & Management page
Related Products
Viral Respiratory Infection Array
SARS-CoV-2 Pooling Test
Vivalytic
Vivalytic Test Menu
Welcome to Vivasuite!
Running within the Bosch IoT cloud maintaining the highest standard of IT security and data privacy. Connectivity ensures that devices are always available and fully updated.
Advantages of Vivasuite:
– Schedule remote software updates
– Know when your devices were last synchronised
– View all devices in one dashboard
– View device information and general device data
– View testing history from one system
– Mobile device monitoring
– Vivalytic user management
– Save time with less “on-device” work
Vivalytic Overview
Discover more about the Vivalytic
Randox Discovery
Randox Discovery | The Benchtop Lab
Discover The Future Of Molecular & Immunoassay Diagnostics
Why Choose the Discovery?
- The Discovery is an exciting and disruptive analyser capable of molecular and immunoassay testing
- Simultaneous detection of hundreds of targets from a single patient sample via patented biochip technology
- Flexible test menu comprising immunoassay and genetic tests for infectious diseases & oncology
- Rapid turnaround time. Three hours to first batch of results with results for subsequent batches every hour after
- Fully automated platform increasing operator walkaway time. A single operator is all that’s required to run up to 3 Discovery analysers
- Simple and easy to use. Intuitive user interface guides the operator through the entire testing process
Discover The Power Of Automation
Randox Discovery is comprised of three interconnected modules which each operate independently performing different aspects of the diagnostic testing process. Each module is separated by a physical barrier to prevent contamination and is accessible via a door. The workflow process runs from right to left and is compatible with lean working principles.
Nucleic Acid Extraction
Module I is responsible for DNA/RNA extraction. After extraction the sample is automatically transferred to Module II. Before transfer, Module I detects the presence of Module II cartridges using a unique vision system.
Multiplex PCR
Module II is responsible for amplification of the extracted nucleic acid by End-Point PCR. UV light is used to sterilise the module and reduce the risk of crossover contamination.
Biochip Hybridisation & Detection
Module III is used in both immunoassay & molecular workflows and is responsible for hybridisation and subsequent detection using patented biochip technology. The detection camera uniquely moves between sample cartridges to detect biochip chemiluminescence.
Discover the Power of Randox Biochip Technology
The Randox Discovery is an exciting and disruptive molecular & immunoassay diagnostic analyser capable of consolidating the normal workload of multiple laboratories, into one compact benchtop platform. Randox patented Biochip Technology allows simultaneous detection of hundreds of targets from a single patient sample. The benefits of multiplexing in this way are endless; allows complete patient profiling, reduces the amount of time spent on individual tests, identifies co-infections, differentiates between pathogens that exhibit similar symptoms and eliminates the need to run multiple time consuming and sample intensive assays. The biochip detection system is based on a chemiluminescent signal, this is the emission of light, without heat, as a result of a chemical reaction.
Discover Our Comprehensive Test Menu
| VIRUSES | ||
| SARS-CoV-2 (COVID-19) | Sarbecovirus (SARS, SARS like, SARS-CoV-2) |
| Detectable Viruses | ||
|---|---|---|
| SARS-CoV-2 (COVID-19) | Sarbecovirus (SARS, SARS like, SARS-CoV-2) | Influenza A |
| Coronavirus 229E/NL63 | Adenovirus A/B/C/D/E | Influenza B |
| Coronavirus OC43/HKUI | Enterovirus A/B/C/D / Rhinovirus A/B/C | Respiratory Syncytial Virus A/B (RSV) |
| Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | Adenovirus A/B/C/D/E | |
*In Development – Respiratory Tract Infections Array, Chronic Lung Infections Array, Sexually Transmitted Infections Array & Urinary Tract Infections Array, KRAS, BRAF & PIK3CA Array, Familial Hypercholesterolemia Array & Cardiac Risk Array.
*In Development – A number of clinical immunoassay arrays covering a range of disease markers including adhesion molecules, alzheimers, anaemia, bone disease, cancer, cardiac, cytokines, diabetes, endocrines, fibrinolysis, fertility, gastrointestinal, metabolic, renal, stroke, thyroid & tissue damage.
*In Development – A number of clinical toxicology arrays are in development covering a wide range of Drugs of Abuse (DoA) & New Psychoactive Substances (NPS) detecting over 500 drug and drug metabolites using innovative Biochip Technology.
Product availability may vary from country to country. Some product may be for Research use Only. For more information on product application and availability, please contact your local Randox Representative.
Discover Randox’s Molecular Platforms
All In One Point Of Care Molecular Platform
Compact, Semi-Automated Benchtop Analyser
